News

A man scrolls through the news on his tablet device

Highlighted news

July 2025: Emollients to Prevent Pediatric Eczema: A Randomized Clinical Trial 

Learn about the the CASCADE trial — a clinical trial led by Dr. Eric Simpson which found that applying a simple, daily moisturizer to a baby’s skin from the first two months—or even earlier—may provide a modest but meaningful reduction in eczema risk by age 2.

March 2023: Dupilumab improves hand, foot atopic dermatitis in phase 3 study

Research results show patients with hand and foot atopic dermatitis experienced significant improvement with dupilumab, which sustained an acceptable safety profile in phase 3 study results.

July 2022: $5 million donor gift establishes first-of-its-kind food allergy center at OHSU

A local couple, Dale and Julie Burghardt, have made a $5 million gift to establish a new Food Allergy Center in the Oregon Health & Science University School of Medicine — the first and only food allergy-focused academic health center in the Pacific Northwest.

Sept. 2021:  FDA approves topical ruxolitinib for atopic dermatitis, first JAK inhibitor for this indication in the U.S.

The first topical JAK inhibitor approved for AD for mild to moderate atopic dermatitis ages 12 years and older– and the first JAK inhibitor approved for this indication – in the United States.

Apr. 2021: Webinar: JAK inhibitors for treating eczema

What are JAK inhibitors and how can they improve the treatment of eczema? Dr. Eric Simpson explains everything the eczema community needs to know about this new class of medications.

May 2021: Topical Steroid Withdrawal (TSW): What the Eczema Community Needs to Know, Now

Examining the poorly understood but potentially debilitating side effect of topic steroid use, Topical Steroid Withdrawal (TSW)

Feb. 2021: Outcome Measures for Atopic Eczema Trials Determined at Latest HOME Meeting

Defining consensus outcome measures for atopic dermatitis (Harmonizing Outcome Measures for Eczema (HOME))

Feb. 2021: Investigators Take Global Look at Best-Practice AD Care

Several universal gaps in diagnosis and treatment of atopic dermatitis (AD) as well as real-world interventions for improvement are the focus of a ground-breaking report.

June 2020: A Roadmap for Navigating the New Eczema Treatment Landscape with Dr. Eric Simpson

Dr. Eric Simpson, a dermatologist with OHSU and leading expert on new eczema treatments, walks us through what’s new in eczema treatments, what’s coming, and how to make sense of it all

Jan. 2020: Rash Decisions; How to Deal with Itchy, Red Skin

National Institutes of Health Article on how to deal with itchy, red skin.

Jul. 2020: Abrocitinib for atopic dermatitis: a step forward

Article published in the Lancet on study drug Abrocitinib (oral treatment) for the treatment of atopic dermatitis.

Oct. 2016: Targeted drug tames atopic eczema in Phase III trials

Study results published in the New England Journal of Medicine show the potential of dupilumab in treating a common, but for some disabling, chronic skin condition for which no current treatments are effective.

Oct. 2016: New Drug for Severe Eczema Is Successful in 2 New Trials

Examining results of Phase III trials for study drug Dupilumab in treating severe eczema.

Non-OHSU news

Highlighted eczema news stories related to non-OHSU faculty

Dec. 2021: Breaking news: FDA approves Adbry™ (tralokinumab-ldrm)

Adbry™ (tralokinumab-ldrm), a biologic medication for adults (18+) with moderate to severe atopic dermatitis (AD) for whom topical prescription treatments have not adequately worked or are not advised, has been approved by the U.S. Food and Drug Administration (FDA)

Sept. 2021: Latest News on Atopic Dermatitis in Children

At Maui Derm NP+PA Fall 2021, Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children.